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To the Editor
Interferon gamma (IFNγ) is a central effector cytokine of
cellular immunity. It is mainly produced by activated T-cells,
natural killer cells and to a lesser extent by professional anti-
gen presenting cells [1]. Its main roles include activation of
macrophages, granuloma formation, and augmentation of
anti-tumor immunity [2]. In addition, it augments antiviral
immunity by inhibiting viral entry, uncoating, translation,
and virion assembly [3].
Although the majority of patients infected by SARS-CoV-
2 virus experience mild symptoms, approximately 15% devel-
op a moderate phenotype resembling viral pneumonia, with a
further subset presenting with severe illness characterized by
hyperinflammation and acute respiratory distress syndrome
[4]. These moderate and severe forms of COVID-19 typically
arise after 7–10 days of illness and are characterized by
hypercytokinemia and a cytokine storm, with high levels of
TNF-α, IL-1β, IL-1Ra, and IL-6 [5, 6].
Neutralizing anti-IFNγ autoantibodies were first described
in 2004 in the context of selective susceptibility to non-
tuberculous mycobacterial (NTM) infection [7, 8]. Lymph
nodes, bones/joints, and lungs are most commonly affected,
with soft tissue and skin involvement (in the form of
neutrophilic dermatosis, erythema nodosum, or exanthema-
tous pustulosis) also commonly reported [7, 9].
Here, we report a case of previously fit 58-year-old man of
Southeast Asian origin, who was found to have autoantibodies
against IFNγ resulting in acquired IFNγ deficiency and NTM
and COVID-19 co-infection (NTM-COV+). He initially be-
came unwell in December 2018. Over the following 12
months, he developed folliculitis; episcleritis; intermittent rash
with abscesses affecting his chest, arms, and hands
(Supplementary Figure 1A, B); weight loss; reduced appetite;
fatigue; arthralgia (hands, shoulders, and spine); cervical and
supraclavicular lymphadenopathy; and intermittent fever with
night sweats.
Investigations revealed a fluctuating leukocytosis (12–33 ×
109/L), with neutrophilia, anemia (nadir 87 g/L), persistent
thrombocytosis, elevated CRP (peak of 100 mg/L), and low
albumin (nadir 28 g/L). Screening tests for autoimmunity,
blood-borne viruses, and syphilis were negative. Three IFNγ
release assays for tuberculosis were indeterminate. Blood mi-
croscopy and culture were negative. PET-CT demonstrated
widespread noncalcified lymphadenopathy in the neck, chest,
and abdomen, with avid fluorodeoxyglucose uptake.
Neutrophilic dermatosis seen in an initial skin sample raised
the possibility of Sweet’s syndrome, although dermal fibrosis
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suggested atypical mycobacterial infection. A cervical lymph
node biopsy sample failed to demonstrate any of the hallmarks
of lymphoproliferative disease. A differential diagnosis of sar-
coidosis or Sweet’s syndrome was made and empirical treat-
ment with prednisolone commenced in December 2019. This
improved his rash, weight loss, and lymphadenopathy, but not
his fever.
In February 2020, he developed right iliac fossa pain,
vomiting, productive cough, and rash. There was significant
leukocytosis (26 × 109/L) and CRP was elevated at 243 mg/L.
CT imaging revealed new splenomegaly and splenic infarcts.
Further dermatology review reported no features of neutro-
phil ic dermatosis , instead resembling dermati t is
(Supplementary Figure 1C); repeat skin biopsy histology
was suggestive of granulomatous interstitial dermatitis. In
light of the patient’s ethnicity, indeterminate IFNγ release
assay for TB, and evolving clinical picture, a provisional di-
agnosis of atypical mycobacterial infection due to IFNγ auto-
antibodies was made. Bone marrow staining and culture dem-
onstrated growth of mycobacterium avium intracellulare
(MAI) after 1 week of incubation. Subsequent mycobacterial
blood culture was also positive for MAI.
Testing for anti-IFNγ antibodies (Ab), using a Bio-Plex
methodology as previously described [10], revealed high titer
anti-IFNγ Ab in NTM/COV+ patient comparable to three
other patients with known autoantibodies against IFNγ
(NTM/COV−) (Figure 1A, Supplementary Figure 3).We then
verified the neutralizing capacity of these antibodies and their
ability to interfere with IFNγ pathway signaling in an ex vivo
setting by functional testing using whole blood or PBMC.
NTM/COV+ patient’s response to, and production of, IFNγ
was measured in three independent experiments and com-
pared to 3 other NTM/COV− patients and to healthy controls
(N = 15). After 24-h stimulation with PHA, IL-12, or a com-
bination of the two, we were unable to detect IFNγ in the
supernatants from the patient samples, suggesting that anti-
IFNγ Abs were neutralizing the endogenously produced
IFNγ (Figure 1B, left panel). This was also observed in sam-
ples taken from NTM/COV− patients. By contrast, the HCs
demonstrated good production of IFNγ in response to both
stimuli. In addition, under the same experimental settings,
stimulation with IFNγ failed to induce IL-12 production in
the NTM/COV+ patient samples (Figure 1B, right panel).
To further demonstrate the neutralizing capacity of the anti-
IFNγ Ab, we activated HC PBMC with LPS or LPS + IFNγ
in the presence of 20% control or NTM/COV+ patient serum,
measuring IL-12 levels after 24-h incubation. Stimulation
with LPS or LPS + IFNγ triggered production of IL-12 from
HC PBMC incubated with control serum, while HC PBMC
incubated with the patient serum failed to produce IL-12
(Figure 1C). This demonstrated that patient serum neutralized
both endogenously produced IFNγ and exogenous IFNγ. The
capacity of patient serum to neutralize recombinant IFNγ was
further confirmed by adding 20% of control or patient serum
to RPMI-containing recombinant IFNγ and measuring IFNγ
levels by Luminex. The patient serum completely neutralized
recombinant IFNγ (Figure 1D). Lastly, we analyzed the pa-
tient’s HLA type to determine whether he carried the high-risk
HLA-DR alleles associated with anti-IFNγ autoantibodies.
The patient was found to carry DRB1*15:02, DRB1*16:02,
and DQB1*05:02 (homozygous), all of which have previous-
ly been reported to increase the risk of developing anti-IFNγ
autoantibodies [11].
Treatment for MAI was started 4 weeks after hospitaliza-
tion. Due to rifabutin-induced hyperbilirubinemia, the patient
was established on ethambutol, azithromycin, and amikacin.
Prednisolone was continued throughout his hospitalization.
Injectable IFNγ-1b (Immukin) treatment [80 μg/2.65 m2
(body surface) 3 weekly] was implemented alongside plasma
exchange, in an effort to raise IFNγ levels and reduce titers of
anti-IFNγ autoantibodies, respectively (Supplementary
Figure 2).
Further immunological investigations showed normal lym-
phocyte profile with reduced naïve T cells 23% (normal 49–
90%). We were interested to determine if the presence of
IFNγ Ab had effects on the distribution of CD4 T-helper-
cells (Th) Th1, Th2, and Th17, since this might have impacted
the patient’s inability to clear the infection. Compared to HC,
the patient had similar proportions of Th1, and TH17 cells,
and slightly reduced Th2 (Supplementary Figure 1D, E).
At day 37 of admission, the patient was tested positive for
SARS-CoV-2 with a nucleic acid amplification test (NAAT)
from a nose and throat swab. A previous swab taken on ad-
mission had been negative. At the time of screening, the pa-
tient was pyrexial (38.1 °C) but had no respiratory symptoms.
Chest imaging demonstrated novel subpleural nodules, but no
changes indicating COVID-19 pneumonia. Between days 50
and 90, nose and throat swab SARS-CoV-2 NAAT tests were
positive on six occasions (Supplementary Figure 2) but were
negative from day 103 onwards. Steroid treatment continued
uninterrupted throughout this period. The patient did not re-
quire oxygen supplementation and had no significant respira-
tory symptoms. He continued to receive regular plasma ex-
change and IFNγ-1b injections. However, this combination
therapy was unlikely to have made a substantial difference in
correcting his acquired immunodeficiency. Serial measure-
ments of anti-IFNγ Ab showed some reduction in titers, but
levels remained high (Figure 1A). Experiments looking at the
effects of patient serum on levels of exogenously administered
IFNγ demonstrated no detectable free IFNγ following incu-
bation with serum (Figure 1D).
He eventually mounted an adequate IgG antibody response
to several viral antigens including the trimeric S protein
(Supplementary Figure 3). However, his MAI infection
remained difficult to control. Plasma exchange and IFNγ-1b
injection were stopped, but azithromycin, ethambutol, and
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rifabutin were continued. In October 2020, hewas treated with
rituximab to good effect. By April 2021, the patient was sys-
temically well. A PET-CT demonstrated no enlarged LN of
focal nodal uptake and his splenomegaly had reduced from 16
to 13 cm. He is due to complete 2 years of anti-MAI therapy
(azithromycin, ethambutol, and rifabutin).
To determine whether autoantibodies to IFNγ are associ-
ated with severity of COVID-19 infection, we tested sera from
three groups; healthy volunteers (HC), healthcare workers
with asymptomatic or predominantly mild COVID-19 infec-
tion (COV-HCW), and patients hospitalized with COVID-19
(COV-PAT). Both the COV-HCW and the COV-PAT group,
showed similarly increased anti-IFNγ Ab levels when com-
pared to healthy controls. However, antibody levels remained
lowwhen compared to the NTM/COV+ patient and the NTM/
COV− disease controls.
We describe here a single patient with autoantibodies to
IFNγ and NTM and COVID-19 co-infection. We investigated
whether severity of COVID19 infection is associated with
anti-IFNγAb by studying two cohorts of infected individuals,
one with severe disease and the other with mild/asymptomatic
disease. The patient with NMT and COVID-19 co-infection,
despite apparent IFNγ deficiency, did not have severe
COVID-19 disease. Exploring associations between anti-
IFNγ Ab and COVID-19 disease severity in a larger cohort
of patients, we found no obvious link. Among infected indi-
viduals, both severe and mild or asymptomatic COVID-19
infection patients had similar levels of anti-IFNγ Ab. These
autoantibodies appear to develop during the course of infec-
tion, since they were not readily detectable in a non-infected
cohort. Furthermore, antibody titers were much lower com-
pared to patients with confirmed acquired IFNγ deficiency.
Fig. 1 A Detection and titration of anti-IFNγ antibody. Patient sera were
diluted in seven 1/5 steps starting at 1/100. Anti-IFNγ IgG was deter-
mined by particle-based flow cytometry on a Luminex analyzer and
shown as mean fluorescence intensities (MFI). B Induced IFNγ and
IL12 levels after whole blood activation. Cytokines were measured in
whole blood after 24-h stimulation using 10 μg/mL PHA or 1 μg/mL
LPS alone or in combination with 20 μg/mL IL12 or 20,000 IU/mL
IFNγ, respectively. To account for lymphopenia, data were corrected
for lymphocyte counts (in response to PHA) or monocyte counts (in
response to LPS). Controls are shown as gray circles (N = 15), patients
with acquired (a)IFNγ deficiency (N3) are shown as blue circles (NTM/
COV−). For the NTM/COV+ patient, data from four experiments are
shown as red circles. Cytokine levels are shown as pg/mL. C In vitro
inhibition of IFNγ using patient serum. Healthy control PBMC were
activated with LPS or LPS + IFNγ in the presence of 20% control (Ct)
or patient (NTM/COV+) serum and IL12 levels were measured in the
supernatant after 24-h incubation. D IFNγ recovery in the presence of
autologous patient (NTM/COV+) serum: 20% control or patient serum
was added to RPMI-containing recombinant IFNγ and IFNγ levels were
determined by Luminex. No IFNγ could be recovered from the well
containing patient serum showing complete antigenic neutralization by
the patient’s autoantibody
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This suggests that anti-IFNγ Ab seen in these two groups of
patents might be a transient phenomenon, with limited neu-
tralizing capacity against IFNγ.
Unlike type I IFNs, which are required for a robust re-
sponse to COVID-19 infection, the role of IFNγ is less clearly
defined. In experimental models using human epithelial cells,
IFNγ has been shown to promote SARS-CoV-2 infection
[12]. Another study demonstrated that lower circulating levels
of IFNγ are associated with more severe COVID-19 infection
course and greater chance of developing lung fibrosis [13],
while the functional exhaustion of both type I and type II
IFN production was independently linked with a severe dis-
ease course [14]. Although serum levels of IFNγ in severe
COVID-19 appear to be significantly lower than is typically
seen in hyperinflammatory disease states such as secondary
hemophagocytic lymphohistiocytosis (HLH) or macrophage
activation syndrome (MAS) [15], IFNγ has been shown to act
synergistically with TNF at a local tissue level, promoting
macrophage activation and lung damage [16, 17].
Our experience suggests that the complete absence of IFNγ
signaling does not result in a worse COVID-19 outcome and
that IFNγ is not necessary to control this virus. However, the
potential role of IFNγ in local hyperinflammatory responses
and lung injury remains ill-defined. Arguably, the mild dis-
ease phenotype in our patient may have resulted from
prolonged corticosteroid therapy rather than impairment of
the IFNγ pathway (or both), given that corticosteroid therapy
has been clearly shown to reduce inflammatory complications
of COVID-19 and improve overall outcomes [18].
Although studies of inborn errors of immunity (IEI) pro-
vide unique insights into functioning of the immune system,
such models are imperfect. The outcomes of COVID-19 in-
fection in patients with various types of IEI have not been easy
to predict. Various retrospective studies show that outcomes
are often better than anticipated [19]. However, other factors
such as age, sex, and comorbidities, known to be associated
with COVID-19 disease severity, also play an important role
[20].
Our study suggests a redundant role of IFNγ to control
SARS-CoV-2 and provides an outline of what to expect when
patients with this rare acquired immune deficiency encounter
a viral illness characterized by immune hyperactivation.
Abbreviations IFNγ, Interferon gamma; ARDS, Acute respiratory dis-
tress syndrome; JAK, Janus kinase; MAS, Macrophage activation syn-
drome; NTM, Non-tuberculous mycobacterium
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s10875-021-01102-7.
Acknowledgements We would like to thank the Royal Papworth
Hospital NHS Trust (RPH) Research and Development Team staff for
their support in recruitment to the study and RPH patients from who
donated serum samples that were used in this study.
Author Contribution MK, VP, HM, and EGK collected clinical informa-
tion; PCA, CC, PH, and GBM performed experiments; RD, GBC, HEB,
and SS analyzed data; and MK, VP, and SS wrote first draft of the
manuscript. HEB and EGK provided sera for COVID-19 patients and
healthy control groups. All authors read, edited, and approved the man-
uscript. RD and SS design and funded the study.
Funding This research is supported by the National Institute for Health
Research (NIHR) Leeds Biomedical Research Centre and grant from
CSL Behring. HEB received funding from the Royal Papworth
Hospital NHS Trust R&D Pump priming award which was used to sup-
port COVID-19 serum surveillance studies.
EGK is supported by the NIHR CRN Greenshoots Award.
Paulina Cortes-Acevedo acknowledges the scholarship and financial
support provided by the National Council of Science and Technology
(CONACyT) number 829997.
GB-M is supported by grants from UNAM, PIAPI2009.
Data Availability The data that support the findings of this study are
available on request from the corresponding author.
Declarations
Ethics Approval Ethics approval was granted by the Leeds (East)
Research Ethics Committee. The study was performed in accordance with
the ethical standards as laid down in the 1964 Declaration of Helsinki and
its later amendments or comparable ethical standards (ethics approval:
IRAS project ID: 96194 REC: 12/WA/0148).
Consent to Participate
Participants provided their consent to participate in this study.
Consent for Publication Consent was sought and gained from the par-
ticipant (the main case) to publish the findings of this study.
Competing Interests The authors declare no competing interests.
Disclaimer The views expressed are those of the authors and not neces-
sarily those of the NHS, the NIHR, or the Department of Health.
References
1. Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ.
Interferon-gamma at the crossroads of tumor immune surveillance
or evasion. Front Immunol. 2018;9:847.
2. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma:
an overview of signals, mechanisms and functions. J Leukoc Biol.
2004;75(2):163–89.
3. MacMicking JD. Interferon-inducible effector mechanisms in cell-
autonomous immunity. Nat Rev Immunol. 2012;12(5):367–82.
4. Fu L,Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical
characteristics of coronavirus disease 2019 (COVID-19) in China: a
systematic review and meta-analysis. J Inf Secur. 2020;80(6):656–
65.
5. Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10
and MCP-3 levels are highly associated with disease severity and
predict the progression of COVID-19. J Allergy Clin Immunol.
2020;146(1):119–27 e4.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical
features of patients infected with 2019 novel coronavirus in
Wuhan. China Lancet. 2020;395(10223):497–506.
7. Doffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S,
Ceron-Gutierrez L, et al. Autoantibodies to interferon-gamma in a
J Clin Immunol
patient with selective susceptibility to mycobacterial infection and
organ-specific autoimmunity. Clin Infect Dis. 2004;38(1):e10–4.
8. Hoflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, Docke
WD, et al. Naturally occurring anti-IFN-gamma autoantibody and
severe infections with Mycobacterium cheloneae and Burkholderia
cocovenenans. Blood. 2004;103(2):673–5.
9. Ku CL, Chi CY, von Bernuth H, Doffinger R. Autoantibodies
against cytokines: phenocopies of primary immunodeficiencies?
Hum Genet. 2020;139(6-7):783–94.
10. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales
G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-
22 in patients with chronic mucocutaneous candidiasis and autoim-
mune polyendocrine syndrome type I. J Exp Med. 2010;207(2):
291–7.
11. Ku CL, Lin CH, Chang SW, Chu CC, Chan JF, Kong XF, et al.
Anti-IFN-gamma autoantibodies are strongly associated with HLA-
DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast
Asia. J Allergy Clin Immunol. 2016;137(3):945–8 e8.
12. Heuberger J, Trimpert J, Vladimirova D, Goosmann C, Lin M,
Schmuck R, et al. Epithelial response to IFN-gamma promotes
SARS-CoV-2 infection. EMBO Mol Med. 2021;13(4):e13191.
13. Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, et al. Lower circu-
lating interferon-gamma is a risk factor for lung fibrosis in COVID-
19 patients. Front Immunol. 2020;11:585647.
14. Ruetsch C, Brglez V, Cremoni M, Zorzi K, Fernandez C, Boyer-
Suavet S, et al. Functional exhaustion of type I and II interferons
production in severe COVID-19 patients. Front Med (Lausanne).
2020;7:603961.
15. Kessel C, Vollenberg R, Masjosthusmann K, Hinze C, Wittkowski
H, Debaugnies F, et al. Discrimination of COVID-19 from
inflammation-induced cytokine storm syndromes by disease-
related blood biomarkers. Arthritis Rheum. 2021.
16. Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L,
Samir P, et al. Synergism of TNF-alpha and IFN-gamma triggers
inflammatory cell death, tissue damage, and mortality in SARS-
CoV-2 infection and cytokine shock syndromes. Cell.
2021;184(1):149–68 e17.
17. Zhang F, Mears JR, Shakib L, Beynor JI, Shanaj S, Korsunsky I,
et al. IFN-gamma and TNF-alpha drive a CXCL10+ CCL2+ mac-
rophage phenotype expanded in severe COVID-19 lungs and in-
flammatory diseases with tissue inflammation. Genome Med.
2021;13(1):64.
18. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL,
et al. Dexamethasone in hospitalized patients with Covid-19. N
Engl J Med. 2021;384(8):693–704.
19. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al.
Coronavirus disease 2019 in patients with inborn errors of immu-
nity: an international study. J Allergy Clin Immunol. 2021;147(2):
520–31.
20. Shields AM, Burns SO, Savic S, Richter AG. Consortium UPC-.
COVID-19 in patients with primary and secondary immunodefi-
ciency: the United Kingdom experience. J Allergy Clin Immunol.
2021;147(3):870–5 e1.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
J Clin Immunol
